News

Immunotherapy shows promise in metastatic cervical cancer


 

AT THE ASCO ANNUAL MEETING 2014

The study was supported by the National Cancer Institute, National Institutes of Health. The authors and Dr. Dizon reported no financial disclosures.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

Launch of rare-cancer trial spurs many more
MDedge Hematology and Oncology
Palliative care consultations improve outcomes, but referrals lag
MDedge Hematology and Oncology
Study suggests robotics have altered hysterectomy landscape
MDedge Hematology and Oncology
First ASCO survivor care guidelines tackle fatigue, anxiety/depression, neuropathy
MDedge Hematology and Oncology
P4 Medicine: A new approach to health and disease
MDedge Hematology and Oncology
Topical lidocaine reduces menopausal dyspareunia
MDedge Hematology and Oncology
AUDIO: Challenges, rewards face creators of pediatric oncofertility clinics
MDedge Hematology and Oncology
Cobas HPV test for first-line screening for cervical cancer
MDedge Hematology and Oncology
ASCO: Extend adjuvant endocrine therapy to 10 years
MDedge Hematology and Oncology
VIDEO: Investigational combo stalls progression in recurrent ovarian cancer
MDedge Hematology and Oncology